Aryl fused azapolycyclic compounds

Details Aryl fused azapolycyclic compounds Aryl fused azapolycyclic compounds

2000-02-25

2003-08-12

Coleman, Brenda (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S210180, C514S210210, C514S228200, C514S228500, C514S232800, C514S248000, C514S253020, C514S253030, C514S256000, C514S257000, C514S286000, C514S289000, C514S295000, C544S058200, C544S060000, C544S125000, C544S126000, C544S233000, C544S242000, C544S247000, C544S343000, C544S361000, C546S043000, C546S063000, C546S074000, C546S097000

Reexamination Certificate

active

06605610

ABSTRACT:

BACKGROUND OF THE INVENTION
This invention relates to aryl fused azapolycyclic compounds, as defined more specifically by formula I below. Compounds of formula I bind to neuronal nicotinic acetylcholine specific receptor sites and are useful in modulating cholinergic function. Such compounds are useful in the treatment of inflammatory bowel disease (including but not limited to ulcerative colitis, pyoderma gangrenosum and Crohn's disease), irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrhythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supranuclear palsy, chemical dependencies and addictions (e.g., dependencies on, or addictions to nicotine (and/or tobacco products), alcohol, benzodiazepines, barbiturates, opioids or cocaine), headache, migraine, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age-related cognitive decline, epilepsy, including petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourette's Syndrome.
The compounds of this invention may also be used in combination with an antidepressant such as, for example, a tricyclic antidepressant or a serotonin reuptake inhibiting antidepressant (SRI), in order to treat both the cognitive decline and depression associated with AD, PD, stroke, Huntington's chorea or traumatic brain injury (TBI); in combination with muscarinic agonists in order to stimulate both central muscarinic and nicotinic receptors for the treatment, for example, of ALS, cognitive dysfunction, age-related cognitive decline, AD, PD, stroke, Huntington's chorea and TBI; in combination with neurotrophic factors such as NGF in order to maximize cholinergic enhancement for the treatment, for example, of ALS, cognitive dysfunction, age-related cognitive decline, AD, PD stroke, Huntington's chorea and TBI; or in combination with agents that slow or arrest AD such as cognition enhancers, amyloid aggregation inhibitors, secretase inhibitors, tau kinase inhibitors, neuronal anti-inflammatory agents and estrogen-like therapy.
Other compounds that bind to neuronal nicotinic receptor sites are referred to in U.S. patent application Ser. No. 08/963,852, which was filed on Nov. 4, 1997. The foregoing application is owned in common with the present application, and is incorporated herein by reference in its entirety.
SUMMARY OF THE INVENTION
This invention relates to aryl fused azapolycyclic compounds of the formula
R
1
is hydrogen, (C
1
-C
6
)alkyl, unconjugated (C
3
-C
6
)alkenyl, benzyl, XC(═O)R
13
or —CH
2
CH
2
—O—(C
1
-C
4
)alkyl;
R
2
and R
3
are selected, independently, from hydrogen, (C
2
-C
6
)alkenyl, (C
2
-C
6
)alkynyl, hydroxy, nitro, amino, halo, cyano, —SO
q
(C
1
-C
6
)alkyl wherein q is zero, one or two, (C
1
-C
6
)alkylamino-, [(C
1
-C
6
)alkyl]
2
amino-, —CO
2
R
4
, —CONR
5
R
6
, —SO
2
NR
7
R
8
, —C(═O)R
13
, —XC(═O)R
13
, wherein said aryl is selected from phenyl and naphthyl, heteroaryl-(C
0
-C
3
)alkyl- or heteroaryl-(C
0
-C
3
)alkyl-O—, wherein said heteroaryl is selected from five to seven membered aromatic rings containing from one to four heteroatoms selected from oxygen, nitrogen and sulfur; X
2
(C
0
-C
6
)alkyl- and X
2
(C
1
-C
6
)alkoxy-(C
0
-C
6
)alkyl-, wherein X
2
is absent or X
2
is (C
1
-C
6
)alkylamino- or [(C
1
-C
6
)alkyl]
2
amino-, and wherein the (C
0
-C
6
)alkyl- or (C
1
-C
6
)alkoxy-(C
0
-C
6
)alkyl- moieties of said X
2
(C
0
-C
6
)alkyl- or X
2
(C
1
-C
6
)alkoxy-(C
0
-C
6
)alkyl- contains at least one carbon atom, and wherein from one to three of the carbon atoms of said (C
0
-C
6
)alkyl- or (C
1
-C
6
)alkoxy-(C
0
-C
6
)alkyl- moieties may optionally be replaced by an oxygen, nitrogen or sulfur atom, with the proviso that any two such heteroatoms must be separated by at least two carbon atoms, and wherein any of the alkyl moieties of said (C
0
-C
6
)alkyl- or (C
1
-C
6
)alkoxy-(C
0
-C
6
)alkyl-groups may be optionally substituted with from two to seven fluorine atoms, and wherein one of the carbon atoms of each of the alkyl moieties of said aryl-(C
0
-C
3
)alkyl- and said heteroaryl-(C
0
-C
3
)alkyl- may optionally be replaced by an oxygen, nitrogen or sulfur atom, and wherein each of the foregoing aryl and heteroaryl groups may optionally be substituted with one or more substituents, preferably from zero to two substituents, independently selected from (C
1
-C
6
)alkyl optionally substituted with from one to seven fluorine atoms, (C
1
-C
6
)alkoxy optionally substituted with from two to seven fluorine atoms, halo (e.g., chloro, fluoro, bromo or iodo), (C
2
-C
6
)alkenyl, (C
2
-C
6
)alkynyl, hydroxy, nitro, cyano, amino, (C
1
-C
6
)alkylamino-, [(C
1
-C
6
)alkyl]
2
amino-, —CO
2
R
4
, —CONR
5
R
6
, —SO
2
NR
7
R
8
, —C(═O)R
13
and —XC(═O)R
13
;
or R
2
and R
3
, together with the carbons to which they are attached, form a four to seven membered monocyclic, or a ten to fourteen membered bicyclic, carbocyclic ring that can be saturated or unsaturated, wherein from one to three of the non-fused carbon atoms of said monocyclic rings, and from one to five of the carbon atoms of said bicyclic rings that are not part of the benzo ring shown in formula I, may optionally and independently be replaced by a nitrogen, oxygen or sulfur, and wherein said monocyclic and bicyclic rings may optionally be substituted with one or more substituents, preferably from zero to two subsbtuents for the monocyclic rings and from zero to three substituents for the bicyclic rings, that are selected, independently, from (C
0
-C
6
)alkyl- or (C
1
-C
6
)alkoxy-(C
0
-C
6
)alkyl-, wherein the total number of carbon atoms does not exceed six and wherein any of the alkyl moieties may optionally be substituted with from one to seven fluorine atoms; nitro, oxo, cyano, halo, (C
2
-C
6
)alkenyl, (C
2
-C
6
)alkynyl, hydroxy, amino, (C
1
-C
6
)alkylamino-, [(C
1
-C
6
)alkyl]
2
amino-, —CO
2
R
4
, —CONR
5
R
6
, —SO
2
NR
7
R
8
, —C(═O)R
13
, and —XC(═O)R
13
;
each R
4
, R
5
, R
6
, R
7
, R
8
and R
13
is selected, independently, from hydrogen and (C
1
-C
6
)alkyl, or R
5
and R
6
, or R
7
and R
8
together with the nitrogen to which they are attached, form a pyrrolidine, piperidine, morpholine, azetidine, piperazine, —N—(C
1
-C
6
)alkylpiperazine or thiomorpholine ring, or a thiomorpholine ring wherein the ring sulfur is replaced with a sulfoxide or sulfone; and
each X is, independently, (C
1
-C
6
)alkylene;
with the proviso that: (a) at least one of R
1
, R
2
and R
3
must be the other than hydrogen, and (b) when R
2
and R
3
are hydrogen, R
1
cannot be hydrogen, (C
1
-C
6
)alkyl, or unconjugated (C
3
-C
6
)alkenyl, and pharmaceutically acceptable salts of such compounds.
Examples of possible heteroaryl groups within the definition of R
2
and R
3
are the following: thienyl, oxazoyl, isoxazolyl, pyridyl, pyrimidyl, thiazolyl, tetrazolyl, isothiazolyl, triazolyl, imidazolyl, tetrazolyl, pyrrolyl and the following groups:
wherein one of R
9
and R
18
is hydrogen or (C
1
-C
6
)alkyl, and the other is a bond to the benzo ring of formula I.
Examples of compounds of this invention are compounds of the formula I, and their pharmaceutically acceptable salts, wherein R
2
and R
3
, together with the benzo ring of formula I, form a bicyclic ring system selected from the following:
wherein R
10
and R
17
are selected, independently, from hydrogen, (C
1
-C
6
)alkyl; and (C
1
-C
6
)alkoxy-(C
0
-C
6
)alkyl- wherein the total number of carbon atoms does not exceed six and wherein any of the alkyl moieties may optionally be substitut

Affiliated with

Also associated with

Rating

Aryl fused azapolycyclic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Aryl fused azapolycyclic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aryl fused azapolycyclic compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3079720